R-CHOP regimen
|
WikiDoc Resources for R-CHOP regimen |
|
Articles |
|---|
|
Most recent articles on R-CHOP regimen Most cited articles on R-CHOP regimen |
|
Media |
|
Powerpoint slides on R-CHOP regimen |
|
Evidence Based Medicine |
|
Clinical Trials |
|
Ongoing Trials on R-CHOP regimen at Clinical Trials.gov Trial results on R-CHOP regimen Clinical Trials on R-CHOP regimen at Google
|
|
Guidelines / Policies / Govt |
|
US National Guidelines Clearinghouse on R-CHOP regimen NICE Guidance on R-CHOP regimen
|
|
Books |
|
News |
|
Commentary |
|
Definitions |
|
Patient Resources / Community |
|
Patient resources on R-CHOP regimen Discussion groups on R-CHOP regimen Patient Handouts on R-CHOP regimen Directions to Hospitals Treating R-CHOP regimen Risk calculators and risk factors for R-CHOP regimen
|
|
Healthcare Provider Resources |
|
Causes & Risk Factors for R-CHOP regimen |
|
Continuing Medical Education (CME) |
|
International |
|
|
|
Business |
|
Experimental / Informatics |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Aparna Vuppala, M.B.B.S. [2]
Synonyms and keywords: Rituximab-Cyclophosphamide-Hydroxydaunorubicin-Oncovin-Prednisone regimen
Overview
R-CHOP regimen refers to an immunochemotherapy regimen consisting of rituximab, cyclophosphamide, hydroxydaunorubicin hydrochloride (doxorubicin hydrochloride), vincristine (Oncovin) and prednisone used to treat both indolent and aggressive forms of non-Hodgkin lymphoma.[1][2]
Regimen
RRituximab
CCyclophosphamide
HDoxorubicin (Hydroxydaunomycin)
OVincristine (Oncovin)
PPrednisone
Indications
References
- ↑ "NCI Thesaurus".
- ↑ "R-CHOP - National Cancer Institute".
- ↑ Coiffier, Bertrand (2002-01-24). "CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma". The New England Journal of Medicine. 346 (4): 235–242. doi:10.1056/NEJMoa011795. ISSN 1533-4406. PMID 11807147. Unknown parameter
|coauthors=ignored (help) - ↑ Kluin-Nelemans, H. C. (2012-08-09). "Treatment of older patients with mantle-cell lymphoma". The New England Journal of Medicine. 367 (6): 520–531. doi:10.1056/NEJMoa1200920. ISSN 1533-4406. PMID 22873532. Unknown parameter
|coauthors=ignored (help)